JP2018529717A5 - - Google Patents

Download PDF

Info

Publication number
JP2018529717A5
JP2018529717A5 JP2018516214A JP2018516214A JP2018529717A5 JP 2018529717 A5 JP2018529717 A5 JP 2018529717A5 JP 2018516214 A JP2018516214 A JP 2018516214A JP 2018516214 A JP2018516214 A JP 2018516214A JP 2018529717 A5 JP2018529717 A5 JP 2018529717A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
antigen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018516214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529717A (ja
JP6764930B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2016/004375 external-priority patent/WO2017056494A1/en
Publication of JP2018529717A publication Critical patent/JP2018529717A/ja
Publication of JP2018529717A5 publication Critical patent/JP2018529717A5/ja
Application granted granted Critical
Publication of JP6764930B2 publication Critical patent/JP6764930B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018516214A 2015-09-29 2016-09-28 アデニンコンジュゲート化合物およびそのワクチンアジュバントとしての使用 Active JP6764930B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562234481P 2015-09-29 2015-09-29
US62/234,481 2015-09-29
PCT/JP2016/004375 WO2017056494A1 (en) 2015-09-29 2016-09-28 Adenine conjugate compounds and their use as vaccine adjuvants

Publications (3)

Publication Number Publication Date
JP2018529717A JP2018529717A (ja) 2018-10-11
JP2018529717A5 true JP2018529717A5 (https=) 2019-11-07
JP6764930B2 JP6764930B2 (ja) 2020-10-07

Family

ID=57138095

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018516214A Active JP6764930B2 (ja) 2015-09-29 2016-09-28 アデニンコンジュゲート化合物およびそのワクチンアジュバントとしての使用

Country Status (8)

Country Link
US (1) US10597397B2 (https=)
EP (1) EP3355933B1 (https=)
JP (1) JP6764930B2 (https=)
CN (1) CN108348618B (https=)
CA (1) CA2998995A1 (https=)
DK (1) DK3355933T3 (https=)
ES (1) ES2805724T3 (https=)
WO (1) WO2017056494A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2805724T3 (es) * 2015-09-29 2021-02-15 Sumitomo Dainippon Pharma Co Ltd Compuestos de adenina conjugados y su uso como adyuvantes de vacunas
JP2021035910A (ja) * 2017-11-01 2021-03-04 大日本住友製薬株式会社 置換プリン化合物
CA3107409A1 (en) * 2018-07-23 2020-01-30 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
EP3936147A4 (en) * 2019-03-04 2022-09-28 JAPAN as represented by DIRECTOR GENERAL of National Institute of Infectious Diseases METHOD OF MANUFACTURE OF AN INFLUENZA HA-SPLIT VACCINE
EP3954382A4 (en) * 2019-04-05 2022-12-21 Sumitomo Pharma Co., Ltd. WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING IT
KR20250038769A (ko) * 2022-07-26 2025-03-19 자임워크스 비씨 인코포레이티드 면역조절제 퓨린 유래 화합물, 이의 접합체 및 이의 사용 방법
WO2024206402A1 (en) * 2023-03-27 2024-10-03 The Cleveland Clinic Foundation Topical pala therapy for cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
NZ504800A (en) 1997-11-28 2001-10-26 Sumitomo Pharma 6-Amino-9-benzyl-8-hydroxy-purine derivatives and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases thereof
US7157465B2 (en) 2001-04-17 2007-01-02 Dainippon Simitomo Pharma Co., Ltd. Adenine derivatives
JP2007514644A (ja) 2003-04-10 2007-06-07 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応を向上させる方法および組成物
EP2939693A1 (en) 2003-08-14 2015-11-04 3M Innovative Properties Company Lipid-modified immune response modifiers
EP1939202A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
ES2552471T3 (es) * 2007-02-07 2015-11-30 The Regents Of The University Of California Conjugados de agonistas de TLR sintéticos y usos de los mismos
AR065784A1 (es) * 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
ES2656813T3 (es) 2008-10-24 2018-02-28 Glaxosmithkline Biologicals Sa Derivados de imidazoquinolina lipidados
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
EP2461690A4 (en) 2009-08-07 2013-03-27 Glaxosmithkline Biolog Sa LIPIDED OXOADENINE DERIVATIVES
US20130202629A1 (en) * 2010-04-30 2013-08-08 The Regents Of The University Of California Uses of phospholipid conjugates of synthetic tlr7 agonists
WO2012011606A1 (en) * 2010-07-20 2012-01-26 Dainippon Sumitomo Pharma Co., Ltd. Process for preparing adenine compounds and intermediates thereof
ES2617451T3 (es) 2010-08-17 2017-06-19 3M Innovative Properties Company Composiciones lipidadas de compuestos modificadores de la respuesta inmunitaria, formulaciones, y métodos
FR2968662B1 (fr) * 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
ES2805724T3 (es) * 2015-09-29 2021-02-15 Sumitomo Dainippon Pharma Co Ltd Compuestos de adenina conjugados y su uso como adyuvantes de vacunas

Similar Documents

Publication Publication Date Title
JP2018529717A5 (https=)
JOP20220069A1 (ar) عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها
JP2013510124A5 (https=)
US20050136065A1 (en) Use of small molecule compounds for immunopotentiation
JP2014511891A5 (https=)
JP2011503045A (ja) Crth2拮抗化合物の使用
JP2016530283A5 (https=)
JP2019521988A5 (https=)
JP2018528192A5 (https=)
JP2013510120A5 (https=)
JP5779091B2 (ja) Iap阻害剤による免疫調節
EP3129379A1 (en) Mertk-specific pyrrolopyrimidine compounds
CN116712552A (zh) 用于治疗疱疹病毒诱导的病况的方法和组合物
EA201490014A1 (ru) Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот
JP2009507896A5 (https=)
JP2018531987A5 (https=)
UY32695A (es) FORMA DE DOSIFICACIÓN FARMACÉUTICA PARA ADMINISTRACIÓN ORAL DE UN INHIBIDOR DE LA FAMILIA Bcl-2
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
JP2020531593A5 (https=)
CA2568608A1 (en) Six membered amino-amide derivatives as angiogenesis inhibitors
JP2016516074A5 (https=)
JP2014505107A5 (https=)
RU2016122731A (ru) Функционализированные и замещенные индолы в качестве противораковых агентов
JP2015529194A5 (https=)
JP2009541387A5 (https=)